Alessia Steffanina1, Lidia Proietti1, Caterina Antonaglia2, Paolo Palange1, Elena Angelici1, Rita Canipari3. 1. Laboratory of Respiratory Pathophysiology, Department of Public Health and Infectious Diseases, Rome, Italy. 2. Department of Pneumology and Respiratory Intensive Care Unit, University Hospital of Cattinara, Trieste, Italy. Laboratory of Respiratory Pathophysiology, Department of Public Health and Infectious Diseases, Rome, Italy. 3. Section of Histology, Department of Anatomy, Histology, Forensic Medicine, and Orthopedics, Sapienza University of Rome, Via A Scarpa 16, Rome, Italy. rita.canipari@uniroma1.it.
Abstract
BACKGROUND: Obstructive sleep apnea syndrome (OSAS) has emerged as a risk factor for cardiovascular disease. A prothrombotic state may affect coagulation and participate in the atherosclerotic process in subjects with OSAS. These alterations in coagulation seem to involve the plasminogen activation system. We evaluated the imbalances of the plasminogen activation system related to OSAS, and we assessed the effects of CPAP on the plasminogen activation system. METHODS: Thirty-nine subjects were submitted to a home-based cardiorespiratory sleep study, and 14 healthy subjects (apnea-hypopnea index < 5) were used as controls. Serum levels of urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), and active transforming growth factor-β (TGF-β) were measured. These molecules were reassessed in only 17 of the subjects after 1 month of CPAP. RESULTS: PAI-1 and tPA were significantly higher in the subjects with OSAS compared with the controls, whereas TGF-β and uPA levels were lower. PAI-1 showed a significant positive correlation with the apnea-hypopnea index, percentage of time spent at O2 saturation < 90%, and oxygen desaturation index, whereas TGF-β was inversely related to all 3 of these parameters. After the CPAP therapy, PAI-1 significantly decreased, whereas TGF-β showed a significant increase, although the values did not reach those of the controls. uPA and tPA did not show significant differences after the treatment. CONCLUSIONS: Our results suggest an imbalance of fibrinolysis related to OSAS and an improvement of the prothrombotic state after the CPAP treatment.
BACKGROUND: Obstructive sleep apnea syndrome (OSAS) has emerged as a risk factor for cardiovascular disease. A prothrombotic state may affect coagulation and participate in the atherosclerotic process in subjects with OSAS. These alterations in coagulation seem to involve the plasminogen activation system. We evaluated the imbalances of the plasminogen activation system related to OSAS, and we assessed the effects of CPAP on the plasminogen activation system. METHODS: Thirty-nine subjects were submitted to a home-based cardiorespiratory sleep study, and 14 healthy subjects (apnea-hypopnea index < 5) were used as controls. Serum levels of urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), and active transforming growth factor-β (TGF-β) were measured. These molecules were reassessed in only 17 of the subjects after 1 month of CPAP. RESULTS:PAI-1 and tPA were significantly higher in the subjects with OSAS compared with the controls, whereas TGF-β and uPA levels were lower. PAI-1 showed a significant positive correlation with the apnea-hypopnea index, percentage of time spent at O2 saturation < 90%, and oxygen desaturation index, whereas TGF-β was inversely related to all 3 of these parameters. After the CPAP therapy, PAI-1 significantly decreased, whereas TGF-β showed a significant increase, although the values did not reach those of the controls. uPA and tPA did not show significant differences after the treatment. CONCLUSIONS: Our results suggest an imbalance of fibrinolysis related to OSAS and an improvement of the prothrombotic state after the CPAP treatment.
Authors: Katie L J Cederberg; Umaer Hanif; Vicente Peris Sempere; Julien Hédou; Eileen B Leary; Logan D Schneider; Ling Lin; Jing Zhang; Anne M Morse; Adam Blackman; Paula K Schweitzer; Suresh Kotagal; Richard Bogan; Clete A Kushida; Yo-El S Ju; Nayia Petousi; Chris D Turnbull; Emmanuel Mignot Journal: Int J Mol Sci Date: 2022-07-20 Impact factor: 6.208
Authors: Ze Zheng; Keiko Nakamura; Shana Gershbaum; Xiaobo Wang; Sherry Thomas; Marc Bessler; Beth Schrope; Abraham Krikhely; Rui-Ming Liu; Lale Ozcan; José A López; Ira Tabas Journal: J Clin Invest Date: 2020-08-03 Impact factor: 19.456